1. Advantages of switching to elvitegravir/cobicistat/emtricitabine/tenofovir therapy in virologically-suppressed people living with human immunodeficiency virus/acquired immune deficiency syndrome. Issue 22 (20th November 2022) Authors: Fan, Lina; Li, Lei; Gao, Liying; Hu, Yue; Yu, Aiping; Zhang, Defa; Qiu, Chunting; Huang, Rong; Wu, Yue; Ma, Ping Editors: Yin, Yanjie Journal: Chinese medical journal Issue: Volume 135:Issue 22(2022) Page Start: 2747 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗